Publikationen, an denen er mitarbeitet Juan Luis García Hernández (43)

2016

  1. Integrative analysis of DNA copy number, DNA methylation and gene expression in multiple myeloma reveals alterations related to relapse

    Oncotarget, Vol. 7, Núm. 49, pp. 80664-80679

  2. Post-transcriptional modifications contribute to the upregulation of cyclin D2 in multiple myeloma

    Clinical Cancer Research, Vol. 22, Núm. 1, pp. 207-217

2015

  1. MicroRNA-223 is a novel negative regulator of HSP90B1 in CLL

    BMC Cancer, Vol. 15, Núm. 1

2013

  1. Genome-wide profiling of methylation identifies novel targets with aberrant hypermethylation and reduced expression in low-risk myelodysplastic syndromes

    Leukemia, Vol. 27, Núm. 3, pp. 610-618

2012

  1. Identification of a novel recurrent gain on 20q13 in chronic lymphocytic leukemia by array CGH and gene expression profiling

    Annals of Oncology, Vol. 23, Núm. 8, pp. 2138-2146

  2. Imatinib therapy of chronic myeloid leukemia restores the expression levels of key genes for DNA damage and cell-cycle progression

    Pharmacogenetics and Genomics, Vol. 22, Núm. 5, pp. 381-388

  3. Incidence and clinical characteristics of myeloproliferative neoplasms displaying a PDGFRB rearrangement

    European Journal of Haematology, Vol. 89, Núm. 1, pp. 37-41

  4. Integration of global spectral karyotyping, CGH arrays, and expression arrays reveals important genes in the pathogenesis of glioblastoma multiforme

    Annals of Surgical Oncology, Vol. 19, Núm. 7, pp. 2367-2379

  5. Molecular Characterization of Chronic Lymphocytic Leukemia Patients with a High Number of Losses in 13q14

    PLoS ONE, Vol. 7, Núm. 11

  6. Response to imatinib mesylate in patients with hypereosinophilic syndrome

    International Journal of Hematology, Vol. 96, Núm. 3, pp. 320-326

2011

  1. Molecular characterization of the region 7q22.1 in splenic marginal zone lymphomas

    PLoS ONE, Vol. 6, Núm. 9

2010

  1. P53 deletion may drive the clinical evolution and treatment response in multiple myeloma

    European Journal of Haematology, Vol. 84, Núm. 4, pp. 359-361

2009

  1. Array comparative genomic hybridization identifies genetic regions associated with outcome in aggressive diffuse large B-cell lymphomas

    Cancer, Vol. 115, Núm. 16, pp. 3728-3737

  2. Effects of imatinib mesylate on normal bone marrow cells from chronic myeloid leukemia patients in complete cytogenetic response

    Leukemia Research, Vol. 33, Núm. 1, pp. 170-173

  3. Mesenchymal stem cells from multiple myeloma patients display distinct genomic profile as compared with those from normal donors

    Leukemia, Vol. 23, Núm. 8, pp. 1515-1527

2008

  1. Transient t(11;17)(q14;q12) in patient with chronic myelogenous leukemia in complete molecular response

    Cancer Genetics and Cytogenetics

2006

  1. Geographic differences in the incidence of cytogenetic abnormalities of acute myelogenous leukemia (AML) in Spain

    Leukemia Research, Vol. 30, Núm. 8, pp. 943-948

  2. Overexpression of the VAV proto-oncogene product is associated with B-cell chronic lymphocytic leukaemia displaying loss on 13q

    British Journal of Haematology, Vol. 133, Núm. 6, pp. 642-645

2005

  1. Gene expression profile reveals deregulation of genes with relevant functions in the different subclasses of acute myeloid leukemia

    Leukemia, Vol. 19, Núm. 3, pp. 402-409

  2. Hematological, immunophenotypic, and cytogenetic characteristics of acute myeloblastic leukemia with trisomy 11

    Cancer Genetics and Cytogenetics, Vol. 160, Núm. 1, pp. 68-72